Article Sidebar

PDF
Date Published: 08/01/2022
Abstract Views: 1328
Views PDF: 987
DOI: https://doi.org/10.51298/vmj.v508i2.1653
Issue
Vol. 508 No. 2 (2021)
Section
Các bài báo
How to Cite
Văn Chỉnh, N. ., Cẩm Anh, P. ., Huy Tuấn Kiệt, P. ., Thị Thanh Hương, T. ., & Thị Thái Hòa, N. . (2022). A LITERATURE REVIEW OF THE COST-EFFECTIVENESS OF TARGETED THERAPIES IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC). Vietnam Medical Journal, 508(2). https://doi.org/10.51298/vmj.v508i2.1653

A LITERATURE REVIEW OF THE COST-EFFECTIVENESS OF TARGETED THERAPIES IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER (NSCLC)

Nguyễn Văn Chỉnh1,, Phạm Cẩm Anh2, Phạm Huy Tuấn Kiệt2, Trần Thị Thanh Hương3, Nguyễn Thị Thái Hòa3
1 Doctor Labo Test Centre, Hanoi Medical Laboratory Diagnostic Joint Stock Company
2 Hanoi Medical University
3 National Cancer Institute

Main Article Content

Abstract

Objects: Targeted therapy in the treatment of non-small cell lung cancer will prolong the patient's life longer than chemotherapy option, but its cost is higher. Therefore, in this study, we will find evidences on the cost-effectiveness of targeted therapy compared with chemotherapy method to provide recommendations in choosing the appropriate treatment. Methods: Conducting a systematic literature review on cost-effectiveness, QALYs,... based on Pubmed, Embase and Cochrane database,... from 2000 to August 2021. Studies used the CHEERS checklist. Results: Six out of 128 results having the full criterions were suitable for the CHEERS checklist and were included in the study. The ICERs of erlotinib, afatinib and osimertinib were $85927.4/QALY, $20758–33416.39/QALY, and $23760.1–51615.1/QALY respectively compared to other chemotherapy treatment options. Conclusion: Erlotinib and afatinib for first-line treatment and osimertinib for second-line treatment options are more cost-effective than chemotherapy methods. Reducing the price of targeted drugs lower than the payment threshold of each country will play a vital value for non-small cell lung cancer patients to have access and the economic outcome could become more favorable.

Article Details

Keywords

Non-small cell lung cancer, cost effectiveness, targeted therapy method

References

1. Vergnenegre A, Massuti B, de Marinis F, et al (2016). Spanish Lung Cancer Group, Italian Association of Thoracic Oncology, and French Lung Cancer Group. Economic Analysis of First-Line Treatment with Erlotinib in an EGFR-Mutated Population with Advanced NSCLC. J Thorac Oncol, 11(6), 801-807.
2. Wang S, Peng L, Li J, et al (2018). A trial-based cost-effectiveness analysis of erlotinib alone versus platinum-based doublet chemotherapy as first-line therapy for Eastern Asian nonsquamous non-small-cell lung cancer. PLoS One, 8(3), e55917.
3. Gu X, Zhang Q, Chu YB, et al (2018). Cost-effectiveness of afatinib, gefitinib, erlotinib and pemetrexed-based chemotherapy as first-line treatments for advanced non-small cell lung cancer in China. Lung Cancer, 127, 84-89.
4. You R, Liu J, Wu DB, et al (2019). Cost-Effectiveness Analysis Of EGFR Mutation Testing And Afatinib Versus Gemcitabine-Cisplatin As First-Line Therapy For Advanced Non-Small-Cell Lung Cancer In China. Cancer Manag Res, 11, 10239-10248.
5. Bertranou E, Bodnar C, Dansk V, et al (2019). Cost-effectiveness of osimertinib in the UK for advanced EGFR-T790M non-small cell lung cancer. J Med Econ; 21(2), 113-121.
6. Guan H, Liu G, Xie F, et al (2019). Cost-effectiveness of Osimertinib as a Second-line Treatment in Patients With EGFR-mutated Advanced Non-Small Cell Lung Cancer in China. Clin Ther, 41(11), 2308-2320.
7. Organisation for Economic Co-Operation and Development (OECD): StatExtracts: PPPs and Exchange Rates. http://stats.oecd.org/Index.aspx?DatasetCode=SNA_TABLE 4.
8. Husereau, Drummond, Petrou, et al (2013). Consolidated Health Economic Evaluation Reporting Standards (CHEERS) Statement. BMJ 2013, 346, f1049–f1049.